<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991962</url>
  </required_header>
  <id_info>
    <org_study_id>2000024671</org_study_id>
    <nct_id>NCT03991962</nct_id>
  </id_info>
  <brief_title>Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma</brief_title>
  <official_title>Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of modified FOLFIRINOX followed by&#xD;
      stereotactic body radiotherapy (SBRT) in patients with borderline resectable pancreatic&#xD;
      cancer (BRPC) and locally advanced pancreatic cancer (LAPC). The primary hypothesis will be&#xD;
      to determine if modified FOLFIRINOX followed by SBRT improves progression free survival (PFS)&#xD;
      compared to historical controls treated with gemcitabine-based chemotherapy with or without&#xD;
      standard fractionated radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary and Secondary are listed below.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      - To evaluate progression free survival after modified FOLFIRINOX and SBRT in borderline&#xD;
      resectable and locally advanced pancreatic cancer.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To evaluate the radiographic response to FOLFIRINOX and SBRT by comparing IV contrast CT&#xD;
           scans before and after therapy.&#xD;
&#xD;
        -  To determine rates of recurrence (local only, systemic only, and both local and&#xD;
           systemic), and overall survival.&#xD;
&#xD;
        -  To determine rates of grade 3 or greater gastrointestinal toxicity, including acute&#xD;
           toxicities occurring within 3 months of treatment, and late toxicities occurring over 3&#xD;
           months after completion of radiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, single group design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>9 months</time_frame>
    <description>Progression-free survival (PFS) at will be judged by CT scan and Response evaluation criteria in solid tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response</measure>
    <time_frame>Within 21 days of starting study drug</time_frame>
    <description>Radiographic response to FOLFIRINOX and SBRT will be done by comparing IV contrast CT scans before and after therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Recurrence</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Rates of recurrence (local only, systemic only, and both local and systemic) will be monitored for up to 3 years depending on time when the initiation of treatment begins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of grade 3 or greater gastrointestinal toxicity</measure>
    <time_frame>Up to 3 months post treatment</time_frame>
    <description>Grade 3 or greater gastrointestinal toxicities will be monitored including acute toxicities occurring within 3 months of treatment, and late toxicities occurring over 3 months after completion of radiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Patients will be monitored for overall survival for up to 3 years depending on time when the initiation of treatment begins.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>mFOLFIRINOX followed by SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive mFOLFIRINOX, followed stereotactic body radiotherapy (SBRT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFIRINOX</intervention_name>
    <description>Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks</description>
    <arm_group_label>mFOLFIRINOX followed by SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiotherapy (SBRT)</intervention_name>
    <description>Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.</description>
    <arm_group_label>mFOLFIRINOX followed by SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
          -  Borderline resectable pancreatic adenocarcinoma or locally advanced pancreatic&#xD;
             adenocarcinoma&#xD;
&#xD;
          -  No evidence of extrapancreatic disease on diagnostic imaging&#xD;
&#xD;
          -  No evidence of invasion into the duodenum or stomach, as determined by EGD/EUS&#xD;
&#xD;
          -  No prior treatment (chemotherapy, biological therapy, or radiotherapy) for pancreatic&#xD;
             cancer&#xD;
&#xD;
          -  No prior treatment with oxaliplatin, irinotecan, fluorouracil, or capecitabine&#xD;
&#xD;
          -  ECOG Performance Status of 0-1&#xD;
&#xD;
          -  No other malignancy within past five years (exceptions include basal cell carcinoma of&#xD;
             the skin, cervical carcinoma in situ, and non-metastatic prostate cancer)&#xD;
&#xD;
          -  No evidence of second malignancy at the time of study entry&#xD;
&#xD;
          -  No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the&#xD;
             lung&#xD;
&#xD;
          -  No &gt; grade 2 sensory peripheral neuropathy&#xD;
&#xD;
          -  No uncontrolled seizure disorder, active neurological disease, or known CNS disease&#xD;
&#xD;
          -  No significant cardiac disease, including the following: unstable angina, New York&#xD;
             Heart Association class II-IV congestive heart failure, myocardial infarction within&#xD;
             six months prior to study enrollment&#xD;
&#xD;
          -  Not pregnant and not nursing&#xD;
&#xD;
          -  No other medical condition or reason that, in the opinion of the investigator, would&#xD;
             preclude study participation&#xD;
&#xD;
          -  Laboratory parameters as follows:&#xD;
&#xD;
               -  Absolute neutrophil count ≥1,500/uL,&#xD;
&#xD;
               -  Platelet count ≥75,000/uL,&#xD;
&#xD;
               -  Hemoglobin ≥9 g,/dL,&#xD;
&#xD;
               -  Creatinine &lt;1.5 X ULN or estimated GFR &gt;30 ml/min,&#xD;
&#xD;
               -  Bilirubin &lt;1.5 X ULN,&#xD;
&#xD;
               -  AST and ALT &lt;3 X ULN,&#xD;
&#xD;
               -  Negative pregnancy test in women of childbearing potential&#xD;
&#xD;
          -  Able to be treated with SBRT only at the Smilow New Haven campus&#xD;
&#xD;
          -  Able to have fiducials placed in the pancreas&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failing to meet any of the Inclusion Criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Johung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Johung, MD, PhD</last_name>
    <phone>203-737-6876</phone>
    <email>kimberly.johung@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Johung, MD, PhD</last_name>
      <phone>203-737-6876</phone>
      <email>kimberly.johung@yale.ed</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Pope, CCRP</last_name>
      <phone>203-737-5801</phone>
      <email>jennifer.pope@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kimberly Johung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

